ABSTRACT Ten patients with respiratory failure and nocturnal hypoventilation were treated for three to nine months by nasal intermittent positive pressure ventilation. Four patients had chronic obstructive lung disease (median FEV, 19% predicted) and six restrictive chest wall disorders (median FVC 25% predicted); eight of the patients also had cardiac failure. The median daytime arterial oxygen tension, measured before and after at least three months' treatment, increased from 6-2 (range 5.4-9.6) to 9 1 (7.1-9.8) kPa in those with restrictive disease (p < 0-05), and from 6-0 (5.7-6 5) to 7 1 (6 3-7 7) kPa in the four with airflow limitation (NS). Median values for arterial carbon dioxide tension over the same time fell from 8-2 (range 6-7-9 8) to 6-5 (6-0-6 9) kPa in the group with restrictive disease (p < 005) and from 8-2 (7.0-9 2) to 7-1 (4.9-7.7) kPa in those with airflow limitation (p < 0 02). Total sleep time while patients were using nasal positive pressure ventilation varied from 155 to 379 (median 341) minutes, and included 4-26% rapid eye movement sleep (median 14%). The percentage of monitored time during the night in which the arterial oxygen saturation was less than 80% fell from a median (range) of 96 (3-100) to 4 (0-9) in the six patients with restrictive disease and from 100 (98-100) to 40 (2-51) in those with airflow limitation. There were no changes in spirometric values but exercise tolerance improved in all patients. The technique may prove an acceptable alternative to long term domiciliary oxygen therapy in selected patients.
Introduction
Nocturnal hypoventilation is a feature of respiratory muscle weakness,' restrictive chest wall disease,2 and chronic obstructive lung disease,3 and is believed to contribute to the development of respiratory and cardiorespiratory failure. Control of this sleep related breathing disturbance relieves symptoms, improves daytime ventilatory function, and prolongs survival. 4 Patients with respiratory muscle weakness have been treated successfully with intermittent positive pressure ventilation delivered through a well fitting nasal mask,56 and we have used the same technique to control nocturnal hypoventilation in patients with restrictive defects or chronic obstructive pulmonary disease.
Patients and methods
We selected 10 patients (eight ofthem men) aged 41-65 years. Four have chronic airflow limitation and six Address for reprint requests: Dr M A Branthwaite, Brompton Hospital, London SW3 6HP. Accepted 15 January 1987 restrictive disorders of the chest wall. Two of the six with restrictive disease (patients 5 and 9) have pulmonary fibrosis secondary to tuberculosis and ankylosing spondylitis respectively, and patient 5 also has airflow limitation (FEV,/FVC ratio 55%). Clinical details are given in table 1. Hypercapnic respiratory failure was found in all the patients at the outset, and eight presented with signs ofcor pulmonale. The six patients with restrictive chest wall disease had had their disease inadequately controlled with protriptyline,' three developed an unacceptable degree of upper airway obstruction when ventilated mechanically in a tank ventilator, and two who had used negative pressure ventilation at home for many months had poor control of their disease and required frequent readmission to hospital. One ambulant outpatient (No 10) had been using a tank ventilator every night in a local hospital for more than a year. Two of the four patients with chronic obstructive lung disease had shown some improvement in diurnal arterial blood gas tensions while using protriptyline but long term treatment was precluded by anticholinergic side effects. Three of these four refused treatment with long term domiciliary oxygen because of the constraint of using it for 15 hours each day, and the fourth developed After the preliminary assessment all patients were acclimatised to intermittent positive pressure ventilation by nasal mask with the apparatus and technique described previously.'* Once they were able to sleep comfortably with the apparatus, oxygen saturation and transcutaneous carbon dioxide tension were recorded during a single night study to conform that optimum settings had been achieved. The patient was then discharged home. One patient (No 5), who developed unacceptable hypercapnia with added oxygen while breathing spontaneously or using negative pressure ventilation during sleep, remained hypoxaemic during nasal intermittent positive pressure ventilation with air and his peripheral oedema failed to resolve. Oxygen with a flow rate of 1 I/min was added through a port on the nasal mask from six months onwards.
All patients were reassessed from three to nine months (median four months) later, when all stated that they had complied with the advice to use the ventilator at home while sleeping at night. Arterial blood gas analysis and spirometry were repeated in the late afternoon while the resting patient breathed air spontaneously. Polysomnography was carried out as described previously on all patients. All subjects were ventilated with air, patient 5 using added oxygen at I 1/min. Analysis of arterial blood confirmed the presence of hypercapnic respiratory failure by day before treatment (median arterial oxygen tension (Pao2) 6-0, range 5-4 96 kPa; median carbon dioxide tension (Paco2) 8-2, range 6 7-9-8 kPa). During sleep arterial oxygen saturation fell and arterial carbon dioxide tension increased in all eight spontaneously breathing subjects, and oxygen saturation fell in the two subjects with chest wall restriction (patients 5 and 6) who were studied while using negative pressure ventilation.
When reassessed at least three months after treatment with nasal intermittent positive pressure ventilation at night, all patients reported symptomatic improvement and an increase in exercise tolerance. In the patients with chronic airflow limitation the six minute walking distance was unchanged in one, fell slightly in another, and increased by more There was an improvement in both arterial oxygen and arterial carbon dioxide tensions in all patients except for one with chest wall restriction, whose Pao2 fell by 0 3 kPa (fig). Arterial Po2 measured during the day increased from a median (range) of 6 2 (54-9 6) to 9-1 (7-1-9-8) kPa in the group with restrictive disease, and from 6-0 (5-7-6 5) to 7-1 (6 3-7 7) kPa in those with airflow limitation. These changes are significant at the 1% level for the group as a whole and at 5% for those with restriction. For patients with airflow limitation the changes in Pao2 were not significant but there was a more obvious improvement in daytime Paco2, which fell from a median (range) of 8:2 (7 0-9-2) to 7-1 PaCO2 (kPa) 10 80% fell from a median (range) of 96% (3-100%) to 4% (0-9%) of the total monitoring time in those with restrictive disease (p<0-05) and from 100% (98-100%) to 40% (2-51%) in those with airflow limitation (p < 0-05). Control of lesser degrees of desaturation was not achieved in the four with chronic airflow limitation (table 2). Hypercapnia during sleep was reduced in all subjects, including the patient who had oxygen added through his nasal mask. The six patients with restrictive disease slept well while using nasal positive pressure ventilation, with a total sleep time of over 330 minutes in all and with rapid eye movement (REM) sleep occupying a median of 16 5% (range 6-26%). The patients with airflow limitation slept less well, both before and during nasal positive pressure ventilation, REM sleep occupying a median (range) of 12 1% (10 3-24%) and 5*3% (4-23%) respectively before and during treatment.
In general the equipment was comfortable and easy to use. Two patients developed minor abrasions over the bridge of the nose, which healed when a light dressing was applied before they used the mask each night. 
